Dermtech Inc Revenue Growth Rates (DMTK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dermtech Inc   (NASDAQ: DMTK)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

DMTK's Revenue Growth by Quarter and Year

Dermtech Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DMTK Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 3.71
FY 3.71

DMTKs Annual Revenue
Dermtech Inc 's Revenue in the fiscal year 2023 $ 15.30 millions
Dermtech Inc 's Revenue in the fiscal year 2022 $ 14.52 millions
Dermtech Inc 's Revenue in the fiscal year 2021 $ 11.84 millions
Dermtech Inc 's Revenue in the fiscal year 2020 $ 5.89 millions
Dermtech Inc 's Revenue in the fiscal year 2019 $ 3.36 millions




DMTK Revenue first quarter 2024 Y/Y Growth Comment
Dermtech Inc reported Revenue growth of 6.7% year on year in the first quarter 2024, to $ 3.71 millions, this is lower than Dermtech Inc 's recent average Revenue rise of 47.13%.

Looking into first quarter 2024 results within Medical Laboratories industry 13 other companies have achieved higher Revenue growth. While Dermtech Inc ' s Revenue increase of 6.7% ranks overall at the positon no. 1640 in the first quarter 2024.


DMTK Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 31.1 % -5.68 % 49.53 %
3rd Quarter September - -11.2 % 17.82 % 122.79 %
2nd Quarter June - -28.84 % 35.58 % 271.43 %
1st Quarter March 6.7 % -6.45 % 47.62 % 61.54 %
FY   - -6.41 % 22.55 % -

Financial Statements
Dermtech Inc 's first quarter 2024 Revenue $ 3.71 millions DMTK's Income Statement
Dermtech Inc 's first quarter 2023 Revenue $ 3.48 millions Quarterly DMTK's Income Statement


DMTK Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 23.66 % -16.25 % 4.62 %
3rd Quarter September - 5.32 % -15.6 % -2.88 %
2nd Quarter June - -13.51 % 13.71 % 23.81 %
1st Quarter March -5.28 % 16.39 % 17.35 % 18.87 %
FY (Year on Year)   - -6.41 % 22.55 % -


Back to DMTK Growth rate Comparisons >> Back to DMTK Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #325
Overall #1640

Revenue Y/Y Growth Statistics
High Average Low
269.55 % 47.13 % -28.94 %
(Dec 31 2021)   (Sep 30 2023)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #325
Overall #1640
Revenue Y/Y Growth Statistics
High Average Low
269.55 % 47.13 % -28.94 %
(Dec 31 2021)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Dermtech Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
395.4 % 29.63 % -45.79 %
(Dec 31 2019)  


DMTK's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Dermtech Inc disclosed decline in Revenue from the fourth quarter by -5.28% to $ 3.71 millions, from $ 3.92 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2024 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Dermtech Inc 's Revenue growth quarter on quarter, overall rank is 499.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #90
Overall #499
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #90
Overall #499
Revenue Q/Q Growth Statistics
High Average Low
395.4 % 29.63 % -45.79 %
(Dec 31 2019)  


DMTK's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Dermtech Inc disclosed decline in Revenue from the fourth quarter by -5.28% to $ 3.71 millions, from $ 3.92 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2024 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Dermtech Inc 's Revenue growth quarter on quarter, overall rank is 499.


Dermtech Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 13.82 $ 13.58 $ 12.65 $ 13.05 $ 14.28
Y / Y Revenue Growth (TTM) -3.22 % -6.45 % -13.87 % -7.73 % 9.55 %
Year on Year Revenue Growth Overall Ranking # 604 # 505 # 130 # 105 # 110
Seqeuential Revenue Change (TTM) 1.74 % 7.35 % -3.07 % -8.58 % -1.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 2173 # 1888 # 1703 # 1483 # 1162


Cumulative Revenue growth Comment
Dermtech Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2023. If the fiscal year would end in Mar 31 2024, Dermtech Inc 's annual Revenue decline would be -3.22% year on year to $14 millions.

In the Healthcare sector 172 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 505 to 604.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 16
Healthcare Sector # 173
Overall # 604

Revenue TTM Y/Y Growth Statistics
High Average Low
101.16 %
 37.08 %
-13.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 357
S&P 500 # 2173
Cumulative Revenue growth Comment
Dermtech Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2023. If the fiscal year would end in Mar 31 2024, Dermtech Inc 's annual Revenue fall would be -3.22% year on year to $14 millions.

In the Healthcare sector 172 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 505 to 604.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 16
Healthcare Sector # 173
Overall # 604

Revenue TTM Y/Y Growth Statistics
High Average Low
101.16 %
37.08 %
-13.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 357
S&P 500 # 2173




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DMTK's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Butterfly Network Inc 11.63%$ 11.631 millions
Myriad Genetics Inc 11.59%$ 11.589 millions
Zomedica Corp 11.58%$ 11.583 millions
Intuitive Surgical Inc 11.45%$ 11.449 millions
Rapid Micro Biosystems Inc 11.44%$ 11.440 millions
Addus Homecare Corp11.36%$ 11.359 millions
Adaptive Biotechnologies Corporation11.23%$ 11.225 millions
Hca Healthcare Inc 11.21%$ 11.212 millions
Koru Medical Systems Inc 10.89%$ 10.892 millions
Universal Health Services Inc 10.85%$ 10.845 millions
Steris Plc10.78%$ 10.781 millions
Bausch Health Companies Inc 10.75%$ 10.751 millions
Cardiff Oncology Inc 10.56%$ 10.557 millions
Radnet Inc 10.53%$ 10.534 millions
Ocular Therapeutix Inc 10.47%$ 10.468 millions
Zynex inc 10.34%$ 10.341 millions
National Healthcare Corp10.24%$ 10.244 millions
Keenova Therapeutics Plc10.19%$ 10.193 millions
Neuronetics Inc 9.96%$ 9.961 millions
Stryker Corp9.73%$ 9.732 millions
Zoetis Inc 9.50%$ 9.500 millions
Edwards Lifesciences Corporation9.45%$ 9.455 millions
Asensus Surgical Inc 9.32%$ 9.324 millions
Pro dex Inc 9.28%$ 9.282 millions
Integer Holdings Corporation9.25%$ 9.255 millions
Gyre Therapeutics Inc 8.99%$ 8.989 millions
Incyte Corporation8.93%$ 8.930 millions
Merck and Co Inc 8.89%$ 8.891 millions
Biomarin Pharmaceutical Inc8.79%$ 8.789 millions
Ati Physical Therapy Inc 8.71%$ 8.710 millions


About Dermtech Inc Revenue Growth Rates (DMTK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dermtech Inc (CIK 1651944).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001651944-24-000047
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dermtech Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.